| Typicality: | 0.548 |
| Saliency: | 0.395 |
| jointly | 3 | manner |
| for orphan diseases | 3 | purpose |
| originally | 2 | other |
| drug → be developed by → company | 13 |
| drug → be developed by → pharmaceutical company | 12 |
| drug → be developed by → the company | 10 |
| drug → be developed by → pharmaceutical companies | 9 |
| drug → be developed by → industry | 6 |
| drug → be developed by → pharmaceutical giant | 5 |
| drug → be developed by → pharmaceutical industry | 3 |
| negative | neutral | positive |
| 0.131 | 0.658 | 0.212 |
| Raw frequency | 58 |
| Normalized frequency | 0.395 |
| Modifier score | 0.900 |
| Perplexity | 216.774 |